Update on key HCC data presented at ASCO GI and EASL-LCS 2022
Update on key HCC data presented at ASCO GI and EASL-LCS 2022
Prof. James Harding
Professor James Harding provides insights on key topics and abstracts in HCC presented at ASCO GI and EASL-LCS 2022.
Prof. James Harding
Medical Oncologist
Memorial Sloan Kettering Cancer Center
United States (US)
Podcast | 
15 min
|
Feb 2022
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimem, respectively
HCC CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer and from Eisai Europe Limited.
Other programmes of interest
28 min
Other programmes developed by Prof. James Harding
Prof. James Harding
Medical Oncologist
Memorial Sloan Kettering Cancer Center
United States (US)
